NetworkNewsAudio – Investment Opportunities in Advanced Bioengineered Drug Delivery

Company: PreveCeutical Medical Inc. (PRVCF)
Category: News

Related Editorial
Hydrogels have been in limited commercial use for more than two decades. However, advancements in drug delivery, and thus hydrogel technology, are driving rapid growth in the global market, which is now projected to surge to over $22 billion by 2022 with a compound annual growth rate (CAGR) of 6.3 percent (, according to BCC Research.  In what may prove to be a groundbreaking approach in this field of exponential opportunity, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) is engineering a unique sol-gel nose-to-brain drug delivery platform to provide clinical relief of multiple physical maladies. Other recognized companies that have embraced new methods of drug delivery and hydrogel delivery systems include Johnson & Johnson (NYSE: JNJ), Valeant Pharmaceuticals International Inc. (VRX: NYSE), UroGen Pharma Ltd. (NASDAQ: URGN) and GW Pharmaceuticals PLC (GWPH: NASDAQ).

To view the full editorial, visit

Contact us: 212.418.1217